Bortezomib

Evidence Level: N/A Predicted Indications: 0

Table of Contents

  1. Bortezomib
    1. Pharmacist Assessment Report
    2. Bortezomib: Known uses and market status in Australia
    3. Summary
    4. Quick overview
    5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
    6. Australia Market Information
    7. Cytotoxicity
    8. Safety Considerations
    9. Disclaimer

Pharmacist Assessment Report

Bortezomib: Known uses and market status in Australia

Summary

The TxGNN model has no candidate with a score of 0.99 or higher for Bortezomib, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item Content
New predicted indications None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug 8
Evidence level Not applicable
Australia Market Status Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items 1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication Source
lymphoma licence in another country
malignant tumor licence in another country
multiple myeloma licence in another country
myeloma licence in another country
Indication Approved category
none none

Relations recorded in the knowledge graph (no approval found)

Indication
b-cell neoplasm
lymphosarcoma
mantle cell lymphoma
plasma cell myeloma

Australia Market Information

Licence Product Dosage form Status
12219D DBL Bortezomib Powder for injection 3 mg Valid

Cytotoxicity

Bortezomib is an antineoplastic drug. Detailed toxicity data were not available in the data compiled for this report, so please refer to the Product Information (PI) warnings and precautions. The following is general guidance only.

Item Content
Cytotoxicity Classification Targeted therapy (proteasome inhibitor)
Myelosuppression Risk Thrombocytopenia and neutropenia are flagged in the knowledge graph contraindication data. Please refer to the PI
Emetogenicity Classification Please refer to the PI
Monitoring Items Full blood count (with platelets and differential), liver function, assessment for peripheral neuropathy
Handling Protection Follow local cytotoxic drug handling procedures and refer to the PI

Safety Considerations

Label-based warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for these.

Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not label text) include:

  • Haematological: thrombocytopenia, neutropenia, agranulocytosis
  • Neurological: peripheral neuropathy, peripheral nervous system disease, posterior leukoencephalopathy syndrome
  • Cardiovascular: cardiovascular disease, heart disease, long QT syndrome, hypotensive disorders, orthostatic hypotension, pulmonary hypertension
  • Respiratory: interstitial lung disease, pneumonia, acute respiratory distress syndrome
  • Gastrointestinal and hepatic: ileus, intestinal obstruction, liver disease, gallbladder disease
  • Metabolic: diabetes mellitus, diabetic ketoacidosis

Drug interactions: The interaction query returned 100 interactions. The first 20 reviewed were mostly Moderate, with a few Minor:

  • Antidiabetic agents (Moderate): acarbose, albiglutide, alogliptin, metformin, pioglitazone, acetohexamide, canagliflozin, chlorpropamide, dapagliflozin, dulaglutide, empagliflozin, ertugliflozin, exenatide. Glycaemic monitoring is advisable.
  • Other Moderate: aprepitant, ascorbic acid, metronidazole, clarithromycin, clotrimazole.
  • Minor: dexamethasone, esomeprazole.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

This site uses Just the Docs, a documentation theme for Jekyll.